Microneedle Patch Delivers Localized Cancer Immunotherapy to Melanoma

 In animal studies, the technique more effectively targeted melanoma than other immunotherapy treatments

Brought to you byNorth Carolina State University
| 3 min read
Register for free to listen to this article
Listen with Speechify
0:00
3:00

Biomedical engineering researchers at North Carolina State University and the University of North Carolina at Chapel Hill have developed a technique that uses a patch embedded with microneedles to deliver cancer immunotherapy treatment directly to the site of melanoma skin cancer. In animal studies, the technique more effectively targeted melanoma than other immunotherapy treatments.

According to the CDC, more than 67,000 people in the United States were diagnosed with melanoma in 2012 alone—the most recent year for which data are available. If caught early, melanoma patients have a 5-year survival rate of more than 98 percent, according to the National Cancer Institute. That number dips to 16.6 percent if the cancer has metastasized before diagnosis and treatment. Melanoma treatments range from surgery to chemotherapy and radiation therapy. A promising new field of cancer treatment is cancer immunotherapy, which helps the body's own immune system fight off cancer.

Related Article: Smart Gels Deliver Medicine on Demand

To continue reading this article, sign up for FREE to
Lab Manager Logo
Membership is FREE and provides you with instant access to eNewsletters, digital publications, article archives, and more.
Add Lab Manager as a preferred source on Google

Add Lab Manager as a preferred Google source to see more of our trusted coverage.

Related Topics

Current Magazine Issue Background Image

CURRENT ISSUE - October 2026

Why Lab Teams Resist Change—And How Leaders Can Respond

Addressing the human side of automation, AI, and operational change

October 2026 Lab Manager Cover Image